|
| | Enalaprilat Basic information |
| | Enalaprilat Chemical Properties |
| Melting point | 148-151°C | | alpha | D -67.0° (0.1M HCl) | | Boiling point | 601.0±55.0 °C(Predicted) | | density | 1.286±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | Very slightly soluble or slightly soluble in water, sparingly soluble in methanol, practically insoluble in acetonitrile. | | form | neat | | pka | pKa 2.30 (Uncertain);3.39 (Uncertain) | | Water Solubility | Soluble in water with heating (~60°C) | | CAS DataBase Reference | 76420-72-9(CAS DataBase Reference) | | EPA Substance Registry System | L-Proline, N-[(1S)-1-carboxy-3-phenylpropyl]-L-alanyl- (76420-72-9) |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 2 |
| | Enalaprilat Usage And Synthesis |
| Description | Enalaprilat is the diacid active metabolite of enalapril. As an injectable ACE inhibitor, it
is reportedly useful in the treatment of uncomplicated accelerated hypertension and
hypertensive emergencies. Enalaprilat is more effective in reducing blood pressure in the
elderly than in the young, despite the fact that renin activity is lower in old age. | | Chemical Properties | White Crystalline Solid | | Originator | Merck (USA) | | Uses | Enalapril is a ACE (angiotensin-converting enzyme) inhibitor, suggested to be more potent than Captopril (sc-200566). Studies indicate that Enalapril downregulates the expression of IL-β, IL-6, and NF-κB. Further studies show that Enalapril upregulates the expression of VEGF and heme oxygenase-1. Enalaprilat reports demonstrate that the compound has some antioxidant activity, which does not include the PKC-NADPH oxidase pathway. | | Uses | Active metabolite of Enalapril. A nonsulfhydryl dipeptide angiotensin converting enzyme (ACE) inhibitor | | Uses | primary hypertension | | Definition | ChEBI: Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension an
heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is g
ven by intravenous injection, usually as the dihydrate. | | Brand name | Vasotec (Biovail);Renitec. |
| | Enalaprilat Preparation Products And Raw materials |
|
